The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China.
Department of Dermatology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
An Bras Dermatol. 2024 May-Jun;99(3):425-432. doi: 10.1016/j.abd.2023.09.003. Epub 2024 Feb 21.
PD-1 (programmed Death-1) immune checkpoint inhibitors have provided significant benefits to tumor patients. However, a considerable proportion of the patients develop immune-related adverse events (irAEs), of which cutaneous irAEs (cirAEs, e.g., psoriasis) occur relatively early. This review provides an overview of the current progress in psoriasis de novo or exacerbation by PD-1 checkpoint inhibitors. It not only describes the relevant influencing factors but also theoretically analyzes the immunological mechanisms that lead to the onset or exacerbation of psoriasis. Finally, the authors present guidelines for the treatment of psoriasis de novo or exacerbation by PD-1 checkpoint inhibitors. The review is intended to assist dermatologists in the early recognition and effective individualized management of such cirAE, which is helpful to continue or adjust the tumor-targeted immunotherapy on the basis of ensuring the quality of life of tumor patients.
PD-1（程序性死亡受体-1）免疫检查点抑制剂为肿瘤患者带来了显著获益。然而，相当一部分患者会发生免疫相关不良反应（irAEs），其中皮肤免疫相关不良反应（cirAEs，如银屑病）发生相对较早。本文综述了 PD-1 检查点抑制剂引发银屑病新发或加重的最新进展。不仅描述了相关影响因素，还从理论上分析了导致银屑病发病或加重的免疫学机制。最后，作者提出了 PD-1 检查点抑制剂引发银屑病新发或加重的治疗指南。本文旨在帮助皮肤科医生早期识别和有效个体化管理此类 cirAE，有助于在保证肿瘤患者生活质量的基础上继续或调整肿瘤靶向免疫治疗。
